John Gregory Beattie net worth and biography

John Beattie Biography and Net Worth

Chief Operating Officer, DSA of Inotiv

Greg joined Inotiv in February 2021 bringing more than 30 years of contract research experience to the company including more than two decades in operational leadership roles at Charles River Laboratories where he drove growth and profitability across multiple business units. Greg held corporate vice president positions within all three of Charles River Laboratories’ segments of operations (Discovery and Safety Assessment, Research Models and Services, and Manufacturing Support).

Among his most significant accomplishments were leading the expansion of several of CRL’s safety assessment sites, establishing a new business venture (Charles River Accelerator and Development Lab) and integrating and expanding CRL’s Global Biologics Testing Solutions business. Greg has extensive experience in strategic planning, leadership development, team building, enterprise-wide system implementation and process improvement.

Greg holds a Bachelor of Science in Biology from McGill University, a Master of Science in Experimental Health Sciences from Université du Quebéc and a Master of Business Administration from the Quantic School of Business and Technology. He is a graduate from the Kellogg Management Institute program at Northwestern University and held certification as diplomate of the American Board of Toxicology (DABT) between 1999 and 2019.

What is John Gregory Beattie's net worth?: The estimated net worth of John Gregory Beattie is at least $1.80 thousand as of December 10th, 2024. Mr. Beattie owns 161,761 shares of Inotiv stock worth more than $1,796 as of October 13th. This net worth approximation does not reflect any other investments that Mr. Beattie may own. Learn More about John Gregory Beattie's net worth.
How do I contact John Gregory Beattie?: The corporate mailing address for Mr. Beattie and other Inotiv executives is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. Inotiv can also be reached via phone at (765) 463-4527 and via email at [email protected]. Learn More on John Gregory Beattie's contact information.
Has John Gregory Beattie been buying or selling shares of Inotiv?: John Gregory Beattie has not been actively trading shares of Inotiv within the last three months. Most recently, on Tuesday, December 10th, John Gregory Beattie bought 30,000 shares of Inotiv stock. The stock was acquired at an average cost of $4.75 per share, with a total value of $142,500.00. Following the completion of the transaction, the chief operating officer now directly owns 161,761 shares of the company's stock, valued at $768,364.75. Learn More on John Gregory Beattie's trading history.
Who are Inotiv's active insiders?: Inotiv's insider roster includes John Beattie (Chief Operating Officer, DSA), Philip Downing (VP), John Sagartz (Insider), and Beth Taylor (CFO). Learn More on Inotiv's active insiders.
Are insiders buying or selling shares of Inotiv?: During the last year, insiders at the sold shares 5 times. They sold a total of 25,817 shares worth more than $10,755.03. The most recent insider tranaction occured on February, 17th when CFO Beth A. Taylor sold 2,888 shares worth more than $837.52. Insiders at Inotiv own 7.8% of the company. Learn More about insider trades at Inotiv.
Information on this page was last updated on 2/17/2026.

John Gregory Beattie Insider Trading History at Inotiv

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Buy	30,000	$4.75	$142,500.00	161,761
12/14/2023	Buy	47,966	$3.12	$149,653.92	111,761
2/22/2023	Buy	5,000	$6.99	$34,950.00	63,795
9/9/2022	Buy	8,900	$22.34	$198,826.00	51,694
2/18/2022	Buy	1,000	$23.88	$23,880.00
2/16/2022	Buy	5,800	$23.71	$137,518.00

John Gregory Beattie Buying and Selling Activity at Inotiv

Inotiv Company Overview

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Today's Range

Now: $0.01

$0.01

$0.02

50 Day Range

MA: $0.02

$0.01

$0.10

2 Week Range

Now: $0.01

$0.08

$2.95

Volume

243,786 shs

Average Volume

7,417,403 shs

Market Capitalization

$387.26 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.77